Biomarkers and clinical outcomes after tezepelumab cessation: extended follow-up from the 2-year DESTINATION study

CONCLUSION: This analysis demonstrates benefits of continued tezepelumab treatment in the management of patients with severe, uncontrolled asthma, compared with stopping treatment after 2 years.PMID:38697286 | DOI:10.1016/j.anai.2024.04.031

Source: Annals of Allergy, Asthma and Immunology - May 2, 2024 Category: Allergy & Immunology Authors: Christopher E Brightling Marco Caminati Jean-Pierre Llanos Scott Caveney Ales Kotalik Janet M Griffiths Anna Lundahl Elliot Israel Ian D Pavord Michael E Wechsler Celeste Porsbjerg Jonathan Corren Monika Go łąbek Neil Martin Sandhia Ponnarambil Source Type: research